Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials.

Schreiber, Anna R; Kagihara, Jodi A; Weiss, Jennifer A; Nicklawsky, Andrew; Gao, Dexiang; Borges, Virginia F; Kabos, Peter; Diamond, Jennifer R

Schreiber, Anna R; Kagihara, Jodi A; Weiss, Jennifer A; Nicklawsky, Andrew; Gao, Dexiang; Borges, Virginia F; Kabos, Peter; Diamond, Jennifer R.

Afiliación

Schreiber AR; Department of Medicine, University of Colorado Anschutz, Aurora, CO, United States.
Kagihara JA; Department of Medicine, University of Colorado Cancer Center, Aurora, CO, United States.
Weiss JA; Department of Medicine, University of Colorado Anschutz, Aurora, CO, United States.
Nicklawsky A; University of Colorado School of Medicine, Aurora, CO, United States.
Gao D; University of Colorado School of Medicine, Aurora, CO, United States.
Borges VF; Department of Medicine, University of Colorado Cancer Center, Aurora, CO, United States.
Kabos P; Department of Medicine, University of Colorado Cancer Center, Aurora, CO, United States.
Diamond JR; Department of Medicine, University of Colorado Cancer Center, Aurora, CO, United States.

Front Oncol ; 11: 640690, 2021.

Article en En | MEDLINE | ID: mdl-33816286

Palabras clave

PD-1 inhibitors; PD-L1 inhibitors; immunotherapy; metastatic breast cancer; phase I clinical trials

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google